{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:50:32Z","timestamp":1769554232935,"version":"3.49.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.8369","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T22:22:01Z","timestamp":1496269321000},"page":"1315-1319","source":"Crossref","is-referenced-by-count":5,"title":["A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia"],"prefix":"10.2169","volume":"56","author":[{"given":"Issei","family":"Tokimatsu","sequence":"first","affiliation":[{"name":"Department of Infection Prevention and Control, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Shigemura","sequence":"additional","affiliation":[{"name":"Department of Infection Prevention and Control, Kobe University Hospital, Japan"},{"name":"Department of Urology, Kobe University Graduate School of Medicine, Japan"},{"name":"Division of Infectious Diseases, Department of International Health, Kobe University Graduate School of Health Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kotaki","sequence":"additional","affiliation":[{"name":"Department of Infection Prevention and Control, Kobe University Hospital, Japan"},{"name":"Division of Infectious Diseases, Department of International Health, Kobe University Graduate School of Health Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Oita University, Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukashi","family":"Yamamichi","sequence":"additional","affiliation":[{"name":"Department of Urology, Hyogo Prefectural Amagasaki General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Tomo","sequence":"additional","affiliation":[{"name":"Blood Purification Center, Oita University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Sanda City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kadota","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Oita University, Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 118: 29-38, 2005.","DOI":"10.1016\/j.amjmed.2005.05.011"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 48: 1012-1016, 2004.","DOI":"10.1128\/AAC.48.3.1012-1016.2004"},{"key":"3","unstructured":"3. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R D 12: 71-100, 2012."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. American Theoretic Society, Infectious Disease Society of America. Guideline for management of adults with hospital-acquired, ventilator-associated, and Healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416, 2005.","DOI":"10.1164\/rccm.200405-644ST"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Albertson TE, Dean NC, El Solh AA, Gotfried MH, Kaplan C, Niederman MS. Fluoroquinolones in the management of community-acquired pneumonia. Int J Clin Pract 64: 378-388, 2010.","DOI":"10.1111\/j.1742-1241.2009.02239.x"},{"key":"6","unstructured":"6. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 59: 115-139, 2000."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Viasus D, Garcia-Vidal C, Cruzado JM. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant 26: 2899-2906, 2011.","DOI":"10.1093\/ndt\/gfq798"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Stass H, B\u00fchrmann S, Mitchell A, et al. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral MFLX administration to patients with severe renal dysfunction. Br J Clin Pharmacol 64: 745-749, 2007.","DOI":"10.1111\/j.1365-2125.2007.02902.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kohno S, Imamura Y, Shindo Y, et al. Clinical practice guidelines for nursing and healthcare-associated pneumonia (NHCAP). Respir Invest 51: 103-126, 2013.","DOI":"10.1016\/j.resinv.2012.11.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mukae H, Kawanami T, Yatera K, et al. Efficacy and safety of levofloxacin in patients with bacterial pneumonia evaluated according to the new "Clinical Evaluation Methods for New Antimicrobial Agents to Treat Respiratory Infections (Second Version)". J Infect Chemother 20: 417-422, 2014.","DOI":"10.1016\/j.jiac.2014.03.009"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kees MG, Weber S, Kees F, Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother 66: 2330-2335, 2011.","DOI":"10.1093\/jac\/dkr282"},{"key":"12","unstructured":"12. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int 11: 62-71, 2007."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Murayama Y, Oozono Y, Kadota J, et al. Clinical and immunological evaluation of infection in patients on hemodialysis. J Infect Chemother 2: 247-253, 1996.","DOI":"10.1007\/BF02355122"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawasaki S, Aoki N, Kikuchi H, et al. Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia? J Infect Chemother 17: 640-645, 2011.","DOI":"10.1007\/s10156-011-0228-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Stass H, Dalhoff A, Kubitza D, Sch\u00fchly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42: 2060-2065, 1998.","DOI":"10.1128\/AAC.42.8.2060"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 39: 455-457, 2012.","DOI":"10.1016\/j.ijantimicag.2012.02.010"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fuharmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 54: 780-784, 2004.","DOI":"10.1093\/jac\/dkh421"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Skalitoni C, Tsaganos T, Stamatiadis D, Giamarellos-Bourboulis EJ, Boletis J, Kanellakopoulou K. Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 29: 575-579, 2009.","DOI":"10.1177\/089686080902900517"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yoshida K, Okimoto N, Kishimoto M, et al. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on PK analysis. J Infect Chemother 17: 678-685, 2011.","DOI":"10.1007\/s10156-011-0282-6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/11\/56_56.8369\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:57:14Z","timestamp":1659056234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/11\/56_56.8369\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.8369","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}